Paliperidone

證據等級: L5

預測適應症: 10 個

Paliperidone: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies

One-Sentence Summary

Paliperidone is an atypical antipsychotic (the active metabolite of risperidone) already established for schizophrenia. The TxGNN model's top-ranked prediction for this drug is Retinal Dystrophy with or without Extraocular Anomalies, but this signal is supported by 0 clinical trials and 15 publications, none of which mention paliperidone, antipsychotics, or any related pharmacology — the evidence pack itself flags this as a likely knowledge-graph false positive rather than a genuine repurposing opportunity.

Quick Overview

Item	Content
Original Indication	Schizophrenia (per evidence-pack rationale; formal TFDA label text not yet available — see Data Gaps)
Predicted New Indication	Retinal Dystrophy with or without Extraocular Anomalies
TxGNN Prediction Score	99.92%
Evidence Level	L5
Finland Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not yet available for paliperidone in this evidence pack (blocking data gap DG002). Based on the analysis embedded in this evidence pack, paliperidone acts as a D2/5-HT2A receptor antagonist, a class mechanism shared with other atypical antipsychotics, and its efficacy in schizophrenia is well established clinically.

However, there is no known or plausible biological link between this mechanism and retinal dystrophy with extraocular anomalies, which is a congenital/genetic ophthalmologic condition typically driven by developmental gene defects rather than monoamine receptor signaling. All 15 literature items returned for this pairing are ophthalmology or craniofacial-anomaly reviews and case reports — none reference paliperidone, antipsychotics, or any pharmacological intervention at all.

Given the absence of any drug-relevant literature, any clinical trials, and any mechanistic rationale, this candidate should be treated as a probable artifact of TxGNN's knowledge-graph proximity scoring rather than a substantiated repurposing hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Note: None of the publications below reference paliperidone or antipsychotic pharmacology — they were retrieved based on disease-term proximity only and are included for completeness/transparency.

PMID	Year	Type	Journal	Key Findings
9416661	1997	Review	Semin Ultrasound CT MR	Overview of orbital infections/cellulitis secondary to sinusitis; not drug-related
20127583	2010	Review	Seminars in Neurology	Clinical approach to diplopia evaluation; not drug-related
38321238	2024	Review	Pediatric Radiology	Imaging differential diagnosis of congenital pediatric ocular pathologies
38249493	2023	Review	Taiwan J Ophthalmol	Review of congenital lens-shape anomalies
22241537	2012	Review	Klin Monbl Augenheilkd	Review of congenital ptosis etiology and management
7035111	1981	Review	Doc Ophthalmol	Wagner-Stickler vitreoretinal degeneration syndrome complex
30196776	2018	Review	J Binocul Vis Ocul Motil	Review of ophthalmoplegia and congenital cranial dysinnervation disorders
24932988	2014	Review	Am J Ophthalmol	Pathogenesis/treatment approach for maculopathy with cavitary optic disc anomalies
33806565	2021	Cohort	Int J Mol Sci	Retinal abnormalities associated with congenital fibrosis of extraocular muscles
109006	1979	Case Report	Am J Ophthalmol	Two cases of unilateral cryptophthalmia with orbital/ocular malformation

Finland Market Information

Paliperidone is currently not marketed in Finland — no product authorizations are on record in this evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA package-insert warnings/contraindications and DDI data are marked as a blocking data gap (DG001) — this prevents a full S1 safety pre-assessment for this drug regardless of indication.

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction lacks any mechanistic rationale, clinical trial support, or relevant literature — it most likely reflects a TxGNN knowledge-graph artifact rather than a real signal. Separately, a blocking safety data gap (missing TFDA label/DDI data) would prevent progression even if the mechanistic case were stronger.

To proceed, the following is needed:

TFDA package insert (warnings, contraindications) and DDI data (DG001, Blocking)
Confirmed original indication and mechanism of action from DrugBank (DG002, High)
If further repurposing work on this drug is desired, redirect evaluation toward treatment-refractory schizophrenia (rank 10 in this same evidence pack), which has an L2 evidence level, a completed Phase 4 real-world study (NCT01860781), and a directly plausible mechanism — a substantially stronger candidate than the top-ranked prediction above.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.